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 Abstract 
We hypothesized that local delivery of GDNF in spinal cord lesion via an injectable alginate 
hydrogel gelifying in situ would support spinal cord plasticity and functional recovery. The 
GDNF release from the hydrogel was slowed by GDNF encapsulation in microspheres 
compared to non-formulated GDNF (free GDNF). When injected in a rat spinal cord 
hemisection model, more neurofilaments were observed in the lesion when the rats were 
treated with free GDNF-loaded hydrogels. More growing neurites were detected in the tissues 
surrounding the lesion when the animals were treated with GDNF microsphere-loaded 
hydrogels. Intense GFAP (astrocytes), low βIII tubulin (neural cells) and RECA-1 
(endothelial cells) stainings were observed for non-treated lesions while GDNF-treated spinal 
cords presented less GFAP staining and more endothelial and nerve fiber infiltration in the 
lesion site. The animals treated with free GDNF-loaded hydrogel presented superior 
functional recovery compared with the animals treated with the GDNF microsphere-loaded 
hydrogels and non-treated animals.  
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 1 Introduction 
 
Neuroprotection and regeneration facilitated by administration of exogenous neurotrophic 
growth factors has been considered as a potential treatment for spinal cord injury (SCI) 
(Wang et al., 2008). Brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic 
factor (GDNF), neurotrophin 3 and 4/5 (NT3 and NT-4/5), and fibroblast growth factor (FGF) 
have already been tested for spinal cord regeneration (Awad et al., 2013). GDNF belongs to 
the transforming growth factor-β superfamily and promotes survival and neurite outgrowth of 
dopaminergic, motor, peripheral sensory, and sympathetic neurons (Chou et al., 2005). In 
addition, the upregulation of GFRα1 and c-Ret gene expression, two GDNF receptors, 
following SCI may further increase the responsiveness of injured neurons and axons to GDNF 
(Widenfalk et al., 2001). Iannotti et al. demonstrated that long-term GDNF intrathecal 
infusion elicited neuroprotective effects on contused adult rat spinal cords, resulting in a 
substantial degree of tissue and axonal sparing (Iannotti et al., 2004). GDNF mRNA 
expression is highly upregulated 8 hours post-SCI and downregulated from 12 hours to 12 
weeks post-SCI (Gerin et al., 2011). Therefore, treatments that promote GDNF-mediated 
survival should be administered by 12 hours post-SCI and should last up to 12 weeks (Hill et 
al., 2008). These data suggest that GDNF treatments during the chronic phases, when 
endogenous GDNF is no longer provided, might be an effective strategy for promoting cell 
survival (Gerin et al., 2011).  
Several strategies have been used to deliver GDNF to the central nervous system, e.g., 
delivery by an infusion pump (Behrstock et al., 2006), gene therapy (Chou et al., 2005), and 
genetic engineering of cells so that they release GDNF (Lu et al., 2003). However, these 
techniques present several disadvantages, such as pump refilling necessity, lack of control of 
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the duration of the transgene expression and the viral spread outside the target area, reduced 
rate of cellular survival within the implanted graft, and immune rejection of the grafted cells 
by the host tissue (Garbayo et al., 2009). An alternative approach is the encapsulation of 
GDNF in biodegradable and biocompatible polylactide-co-glycolide (PLGA) microspheres 
that allow controlled, sustained, and localized delivery in addition to protect the GDNF from 
enzymatic degradation (Garbayo et al., 2009; Wang et al., 2008).  
To combine sustained release and GDNF localization at the lesion site, a drug-delivery system 
composed of GDNF-loaded microspheres dispersed within an alginate hydrogel was selected. 
Injectable matrices require less invasive surgeries, shortening the surgical operation time and 
reducing the post-operative loss of function, pain, and scar size (Zhao et al., 2010). Several 
hydrogels have been investigated for use in spinal cord regeneration (Slaughter et al., 2009), 
including alginate. Alginate has been widely used for drug delivery and cell encapsulation and 
as an injectable cell transplantation vehicle due to its biocompatibility, low toxicity, and 
relatively low cost (Tan et al., 2009). Its solid, non-injectable form has also been used for 
spinal cord regeneration (Erdogan et al., 2010; Kataoka et al., 2004; Prang et al., 2006; Tobias 
et al., 2005). When co-injected with calcium into the lesion, alginate can gelify in situ and fill 
the spinal cord lesion (des Rieux, unpublished data). 
We hypothesized that the delivery of GDNF from a hydrogel directly injected into a spinal 
cord lesion could stimulate spinal cord plasticity and functional recovery. The objectives were 
then to: i) evaluate the influence of GDNF encapsulation on its release from alginate 
hydrogels; ii) study the influence of GDNF formulation on neurite growth; and iii) evaluate 
functional recovery in a rat hemisection model of SCI. 
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 2 Materials and methods 
2.1 Materials 
 
Human recombinant GDNF was obtained from Invitrogen (Carlsbad, CA, USA). Alginate 
was purchased from Pronova (Ultrapure MVG alginate, Mw > 200 kDa, produced under 
GMP guidelines by fermentation from non-animal origin material, FMC BioPolymers, 
NovaMatrix, Philadelphia, PA). Calcium chloride (CaCl2) was purchased from Sigma-Aldrich 
(Saint Louis, MO, USA). The used fibrinogen was a component from a Tisseel™ fibrin 
sealant kit, kindly provided by Baxter Innovations GmbH Inc. (Wien, Austria). A GDNF 
enzyme-linked immunosorbent assay kit (GDNF Emax® ImmunoAssay System, ELISA) was 
purchased from Promega (Madison, WI, USA). Polyclonal anti-GDNF antibody was obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Polylactic-co-glycolic acid (PLGA) 
RG 503H (MW 34 kDa) was provided by Boehringer-Ingelheim (Ingelheim, Germany). 
Dichloromethane, acetone, dimethylsulphoxide, and glycerine were obtained from Panreac 
Quimica S.A. (Barcelona, Spain). Polyvinyl alcohol (88% hydrolyzed, MW: ~ 125,000) was 
obtained from Polysciences, Inc. (Warington, USA). Rat pheochromocytoma PC-12 cells 
were purchased from the American Type Culture Collection (ATCC) (Rockville, MD, USA). 
The Transwell® inserts were provided by Corning (NY, USA). General laboratory reagents 
were purchased from Sigma–Aldrich unless otherwise specified.  
 
2.2 GDNF encapsulation in PLGA microspheres by TROMS 
Among the methods used to encapsulate GDNF, the Total Recirculation One-Machine System 
(TROMS) method is a very gentle technique that avoids shear stress, allowing high 
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encapsulation efficiency and producing very homogeneous batches on a semi-industrial scale 
(Garbayo et al., 2009).  
GDNF-loaded microparticles were prepared with a solvent extraction/evaporation method 
using the TROMS technology (Garbayo et al., 2009). Briefly, the organic solution containing 
the polymer was injected through a needle with an inner gauge diameter of 0.25 mm at 
38 ml/min into the inner aqueous phase to form the first emulsion. The inner aqueous phase 
contained 100 µg of GDNF in 10 mM phosphate, 50 mM sodium chloride (PBS), pH 7.9, 
5 mg HSA, and 5 µl PEG 200. The primary emulsion (W1/O) was recirculated through the 
system and was injected into 20 ml of the external aqueous phase (W2) composed of 0.5% 
PVA. The turbulent injection through the needle with an inner gauge diameter of 0.25 mm 
resulted in the formation of a multiple emulsion (W1/O/W2), which was further homogenized 
by circulation through the system for another 30 seconds. The W1/O/W2 emulsion was stirred 
at 1000 rpm at room temperature for 4 h to allow solvent evaporation and microsphere 
formation. Finally, the GDNF-loaded microspheres were washed with ultrapure water by 
centrifugation and then freeze-dried.  
The mean particle size and size distribution of the microspheres were determined with laser 
diffractometry using a Mastersizer-S® (Malvern Instruments, Malvern, UK). The 
microspheres were dispersed in ultrapure water and analyzed under continuous stirring. The 
average particle size was expressed as the volume mean diameter in micrometers (n=3). To 
determine microparticle protein content 0.5 mg of loaded microparticles were dissolved in 20 
µl DMSO (n=3). PBS was added to dilute the sample for western blot analysis. SDS-PAGE 
was performed onto 12% polyacrylamide gels. Proteins were then transferred onto 
nitrocellulose membranes. Membrane was blocked during 2h at room temperature with Tris-
Buffered Saline 0.05% Tween (TBST) pH 7.4 containing 5% (w/v) of nonfat dried milk. 
Incubation with 1:2000 rabbit antihuman GDNF antibody (SantaCruz Biotechnology, Santa 
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Cruz, USA) diluted in blockade solution lasted 2 h at RT. Horseradish peroxidase (HRP)-
conjugated donkey anti-rabbit IgG antibody (GE Healthcare-Amersham) diluted 1:2000 in 
blockade solution,1 h, RT, was performed to detect bounded antibody. Chemiluminescence 
detection was performed using LumiLight Plus western blotting substrate (Roche Diagnostics, 
Mannheim, Germany). The GDNF signal was quantified by densitometry using the Quantity 
One software (Bio-Rad Laboratories, Inc., Munich, Germany). Samples containing defined 
quantities of GDNF were prepared under the same conditions (PBS and DMSO) and used as 
standard curve. 
 
2.3 GDNF-loaded hydrogel preparation 
A 0.5% (w/v) alginate solution (Pronova UPMVG (medium viscosity, 60% guluronate), FMC 
BioPolymers, NovaMatrix, Philadelphia, PA) was prepared in MilliQ water, incubated with 
charcoal for 30 min, and filter sterilized (MillexTM, MA). The endotoxin level of 
NovaMatrix alginates is guaranteed to be below 100 EU/g.  
A 50 mM calcium chloride (CaCl2) solution was prepared in MilliQ water and sterilized by 
filtration. Alginate hydrogels were formed by the co-injection of 0.5% alginate and 50 mM 
CaCl2 solutions. Fibrinogen was added to the alginate (5 mg/ml) to improve its 
biocompatibility. The fibrinogen used was a component of the Tisseel™ fibrin sealant kit, 
kindly provided by Baxter Innovations GmbH Inc., and was reconstituted with the supplied 
aprotinin solution at 100 mg/ml. Free GDNF (0.5 µg/µl) or GDNF-loaded microspheres were 
mixed with the 0.5 % alginate:fibrinogen solution prior to gelification. 
 
2.4 In vitro GDNF release profiles 
In addition, 2 µg of GDNF, either in solution (free) or encapsulated (microspheres), was 
incorporated into 300 µl of the alginate:fibrinogen solution, and hydrogels were formed by 
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the addition of CaCl2 (n=3). The hydrogels were incubated in PBS + 0.01% sodium azide and 
0.5% BSA at 37°C for 1 month. The amount of released GDNF was measured using a 
sandwich ELISA (GDNF Emax® ImmunoAssay System, Promega) and was expressed as a 
percentage of the incorporated GDNF. 
 
2.5 In vitro bioactivity assay of released GDNF 
The bioactivity of the GDNF released from the alginate:fibrinogen hydrogel was assessed 
using a PC-12 neurite outgrowth bioassay (Garbayo et al., 2007). PC-12 cells were plated 
onto a 12-well culture plate at a low density (2 × 103 cells/cm2). Then, 24 hours later, free 
GDNF-loaded alginate:fibrinogen hydrogels (0.5 µg GDNF in 300 µl of hydrogel) were 
formed in the apical compartment of the 0.45-µm Transwell® inserts that were placed in the 
12-well plate containing the cells (n=6), allowing the GDNF to diffuse through the gel and to 
reach the PC12 cells. Neurite outgrowth was visualized 7 days later under phase-contrast 
illumination with an Accu-Scope inverted microscope connected to a Micrometrics digital 
camera. PC-12 cells incubated with 50 ng/ml of recombinant NGF were used as a positive 
control. 
 
 
2.6 GDNF-loaded hydrogel injection into a rat spinal cord hemisection model   
The animal experiments were approved by the ethical committee for animal care of the health 
science sector of Université catholique de Louvain. Female Long Evans rats (Janvier, Saint 
Berthevin, France) were anesthetized using a rodent anesthesia system (Equipement 
Veterinaire Minerve, Esternay, FR) with vaporized isoflurane (Isoba, Schering-Plough 
Animal Health, Merck Animal Health, Boxmeer, NL) prior to a laminectomy at T9-10 and 
exposure of the spinal cord. A lateral hemisection resulting in a gap of 4 mm along the rostro-
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caudal axis and extending up to the midline was created with a microscalpel in the left side of 
the spinal cord (De Laporte et al., 2009a; De Laporte et al., 2009b). Hydrogel (10 µl) was 
formed by the co-injection in the injury of an alginate solution and a CaCl2 solution with a 
double syringe system (30G insulin syringes), and gelation occurred within 5 min. No gel was 
injected into the untreated operated animals (negative control). Then, paravertebral muscles 
were sutured on the midline, and the skin was stapled. Post-operative care included the 
subcutaneous administration of Baytril (enrofloxacin, 2.5 mg/kg s.c., once per day for 2 
weeks), buprenorphine (0.01 mg/kg s.c., twice per day for 3 days), and lactated Ringer’s 
solution (5 mL/100 g, once per day for 5 days). In addition, the bladder was expressed twice 
per day until bladder function recovered. To study the influence of GDNF formulation, and 
thus GDNF release kinetics, on the damaged spinal tissues, free GDNF and GDNF-loaded 
microspheres were incorporated in alginate:fibrinogen hydrogels and injected into the rat 
spinal cord hemisection model (n=12). Non-treated operated animals were used as negative 
controls. For the experiments, 10 µl of the alginate:fibrinogen hydrogel was loaded with 2 µg 
of GDNF and injected.  
 
2.7 Immunohistochemistry and immunofluorescence analyses of spinal cords 
At 6 weeks and 3 months post-implantation, the rats were transcardially perfused with 4% 
phosphate-buffered formaldehyde to fix the tissues.  
Immunohistochemistry 
The injury site was embedded in paraffin and sliced transversally into 12-µm-thick sections. 
Every section was collected and processed for immunohistochemical analysis. Primary 
antibodies against neurofilaments (mouse anti-pan-neurofilament, 1/1000, Covance, 
Emeryville, CA) and growth-associated protein (mouse anti-GAP43, 1/10000, Millipore, 
Temecula, CA) were used in combination with a secondary immunoperoxidase stain 
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(biotinylated anti-mouse IgG (Vector Laboratories, Burlingame, CA, 1:200). The staining was 
performed with an ABC Elite kit (Vector Laboratories) and DAB (Sigma). Hematoxylin was 
used as a counterstain. Negative controls were generated by omitting the primary antibodies. 
Image acquisition was performed using a MIRAX (Zeiss, Zaventem, BE) slide scanner, 
allowing the acquisition of entire sections. The level of staining (4-6 sections/rat, n=4 per 
group) was quantified using Frida software (The Johns Hopkins University). Neurofilament 
staining was quantified within the lesion (zone delimited on morphological observations), 
while GAP43 (growing neurites) was quantified in a spinal cord portion centered on the lesion 
by an investigator blinded to the treatment. This latter spinal cord portion extended from 3250 
µm rostral to 3250 µm caudal of the lesion and for the entire width of the section. 
 
Immunofluorescence 
The hemisected spinal cord was stained using the whole mount staining method (WMS) as 
previously described (Kardon, 1998). WMS involves the staining of small pieces of tissue 
without sectioning onto slides first. The spinal cords were cut transversally in two equal parts 
and were stained for endothelial cells (mouse anti-RECA IgG1, 1/75, AbD Serotech, Oxford, 
UK), neuronal cells (mouse anti-βIII tubulin IgG2a, 1/500, Covance), and astrocytes (rabbit 
anti-glial fibrillary acidic protein [GFAP], 1/200, Abcam, Cambridge, UK). Alexa® Fluor 647 
goat anti-mouse IgG1 (γ1), Alexa® Fluor 488 goat anti-mouse IgG2a (γ2a), and Alexa® Fluor 
594 goat anti-rabbit IgG (H+L) (Life Technologies, Eugene, OR, USA) secondary antibodies 
were used for the detection of endothelial cells, βIII tubulin, and GFAP, respectively. Once 
the immunofluorescence was completed, the tissues were vitrified. Each half was imaged 
(300-500 µm stacks) with a Cell Observer Spinning Disk (Zeiss). The image stacks were 
merged using AxioVision (Zeiss), and the adjacent zones were assembled using Adobe 
Photoshop. 
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 2.8 Assessment of the functional recovery of the rats using Catwalk™ 
The functional recovery of the rats was evaluated using the Catwalk™ test (Catwalk 7, 
Noldus, Wageningen, The Netherlands). The paw angle and base of support (BOS) of the 
hind paws and the intensity of left hind paw (injured side) were studied. Paw print recording 
allowed analysis of various aspects of walking steps, such as the BOS, the intensity of the 
paw prints, the duration of contact with the floor (stance phase duration), and the sequence 
regularity of steps. Paw angle is an estimate of the angle in degrees of the paw axis relative to 
the horizontal plane. The BOS is the average width between the hind or front paws. The 
‘intensity’ parameter refers to the intensity of the paw prints that is detected by the system 
during gait and is related to weight support by the paws. Up to 5 runs were recorded per 
animal, and analysis was performed on the fastest uninterrupted run (<2s) by blinded 
experimenters (Mignion et al., 2013). The rats were trained 2 weeks before surgery, and the 
runs were recorded just before the surgery; 9 and 14 days; and 1, 2, and 3 months following 
surgery. The BOS, paw angle of hind paws, and intensity of the left hind paw (the side 
affected by the surgery) were considered. Five rats per group were used in these behavioral 
experiments.  
 
2.9 Statistical analysis 
Statistical analyses were performed using PRISM (GraphPad Software, CA, USA). One-way 
or two-way ANOVA with post hoc Bonferroni multiple comparison tests were performed; p-
values between 0.05 and 0.001 were considered significant (*** p<0.001, ** p<0.01, * 
p<0.05). Error bars represent the standard error of the mean in all figures except for Figure 1, 
where they represent the standard deviation. 
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 3 Results 
 
3.1 Formulation of alginate hydrogel and GDNF-loaded PLGA microspheres 
For this study, 0.5% MVG alginate, supplemented with fibrinogen (5 mg/ml v/v), was 
selected based on a previous study (des Rieux, unpublished data). It was well tolerated by 
cells and spinal cord tissues and allowed the sustained release of VEGF.  
GDNF was encapsulated in PLGA-based microspheres using the TROMS technique with a 
88% encapsulation efficiency and a loading of 1.75 µg/mg of microspheres. The mean 
microsphere diameter was 12.3 ± 2.78 µm. 
 
3.2 Influence of GDNF formulation on its release from alginate:fibrinogen hydrogel 
The in vitro release of GDNF, either in its free form or encapsulated in PLGA microspheres, 
was measured. Different release profiles were observed for the free GDNF and GDNF-loaded 
microspheres incorporated into the alginate:fibrinogen hydrogel (Figure 1). GDNF release 
from microspheres was 2.5-fold slower than free GDNF release (28% versus 70%, 
respectively). A total of 25% of the GDNF encapsulated in microspheres was released within 
14 days, and the release then reached a plateau (less than 0.3%/day). Free GDNF was rapidly 
released the first 4 days (30%, 7.5% per day), and the release then slowed down progressively 
to 2.3%/day over the 12 following days and to 0.93%/days over the remaining 2 weeks. A 
small burst release was observed for the two formulations (6.7 % and 4.3 % after 4 hours for 
free GDNF- and GDNF microsphere-loaded hydrogels, respectively). Release of free GDNF 
from the hydrogel showed a good fit to the Higuchi model (R2=0.9674) (Figure 1, insert) 
(Gunduz et al., 2013). This indicates that free GDNF release from the hydrogel occurred 
mainly by diffusion. GDNF release from microspheres incorporated in the hydrogel was first 
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fitting the Higuchi model, followed by a very slow release. GDNF was probably first released 
by desorption from microsphere surface and then by microsphere degradation. 
 
3.3 Bioactivity of GDNF released from the alginate:fibrinogen hydrogel 
The bioactivity of the GDNF released from the alginate:fibrinogen hydrogel was assessed by 
assaying its capacity to induce PC12 cell differentiation into a neuronal phenotype 
characterized by the presence of neurites. The bioactivity of the GDNF released from 
microspheres has been previously demonstrated (Garbayo et al., 2009). Here, the objective 
was to study the influence of GDNF incorporation in alginate:fibrinogen hydrogel on its 
bioactivity once released from the hydrogel. 
Whereas no neurites were observed for the cells cultured with the alginate:fibrinogen 
hydrogel alone, PC12 cells cultured with DMEM supplemented with NGF or with GDNF-
loaded hydrogels developed neurites (Figure 2). This assay demonstrated the bioactivity of 
GDNF after its release into the culture medium.  
 
3.4 Influence of GDNF release profiles on neurite outgrowth 
The hemisected spinal cords of rats were injected with either free GDNF-loaded hydrogels or 
GDNF microsphere-loaded hydrogels, and non-treated operated animals were used as 
controls. The presence of neurites in the lesion and of neurite growth around the lesion site 
was evaluated at 6 weeks and 3 months post-injection. Neurofilament staining highlighted 
neurites, whereas GAP43 staining revealed growing neurites.  
At 6 weeks and 3 months post-injection, residual hydrogel could be observed in the lesion site 
(Figure 3). For non-treated operated animals, the tissue filling the defect was largely 
composed of fibrous scarring, whereas the tissue that was formed in the lesion site treated 
with GDNF-loaded hydrogels was denser and more homogenous.  
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Hemisections filled with free GDNF-loaded hydrogel displayed more neurofilament staining 
at 6 weeks (2-fold more compared with non-treated (p<0.01) and GDNF microsphere-treated 
animals (p<0.05)) (Figure 3A and 4a). After 3 months, more neurofilaments were observed 
for rats injected with free GDNF (2.2-fold, p<0.01) and GDNF microspheres (1.8-fold more, 
p<0.1) compared with controls (Figure 3A and 4b). Neurofilament staining decreased 
between 6 weeks and 3 months for the non-treated and free GDNF-treated rats (1.6-fold less) 
but did not decrease for GDNF microsphere-treated rats (0.56% at 6 weeks and 0.6% at 3 
months).  
At 6 weeks, 3 to 4-times more GAP43 immunoreactivity was detected in GDNF microsphere-
loaded hydrogels compared with free GDNF-treated (p<0.05) and non-treated rats (p<0.01) 
(Figure 3C and 4c). The percentage of GAP43 positive staining decreased over time, slightly 
more for the non-treated (1.85-fold less) than for the GDNF-treated animals (1.3-folds less). 
At 3 months, the GAP43 staining was still more important for GDNF microsphere-loaded 
hydrogels than for free GDNF-treated and non-treated rats (p<0.05) (Figure 3D and 4d). 
Growing neurites were mainly observed at the lesion periphery and surrounding tissue but not 
directly within the lesion (Figure 4D).  
WMS was applied for the first time to adult spinal cord tissues. To a certain extent, 
visualization was allowed to assess the influence of GDNF treatment on tissue organization. 
By performing immunofluorescence staining of entire tissues, this technique provides a more 
accurate idea of the tissue organization. Intense GFAP (astrocytes, red), low βIII tubulin 
(neuronal cells, green), and RECA-1 (endothelial cells, white) stainings were observed for 
non-treated lesions (Figure 5a). Cavities, bordered by astrocytes, could also be seen. The 
GDNF-treated spinal cords presented less GFAP staining and more endothelial and nerve 
fiber infiltration in the lesion site (Figure 5b and 5c). Some hydrogel remains were detectable, 
filling part of the hemisection in which neurites, endothelial cells and blood vessels were 
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detected. Some level of organization was also visible, particularly in the spinal cords injected 
with GDNF microsphere-loaded hydrogels (Figure 5c).  
 
3.5 Influence of GDNF delivery on the gait of spinal cord injured rats 
The gait of each rat was followed over time using the Catwalk™ system to assess the effect of 
GDNF delivery on functional recovery.  
The hind paw angle of both the non-treated and GDNF microsphere-treated rats progressively 
increased from 12° to 50-70° at 3 months, whereas the free GDNF-treated rat value remained 
close to the pre-op value (19° after 3 months versus 14°) (p<0.05) (Figure 6a). Positive angle 
values indicate an outward position of the paw, relative to the horizontal plane, during stance.  
Previously, it was reported that thoracic spinal cord injury does not affect the BOS of the 
front paws but leads to an increase in the BOS of the hind paws (Deumens et al., 2013; 
Hamers et al., 2001). In our study, we observed the opposite: lower BOS values and higher 
paw angles reflected the position of the hind paws of injured rats with knees close to each 
other and paws facing outwards. The hind paw BOS of all groups decreased post-surgery. 
After one month, the BOS values of the hind paws of the free GDNF-treated animals were 
closer to pre-op values, whereas the BOS of non-treated and GDNF microsphere-treated rats 
were 2-fold lower (p<0.05) (Figure 6b). At two months post-surgery, there was no significant 
difference between the values according to GDNF formulation, and both BOS values were 
significantly higher than the values observed in non-treated rats (3.6-fold higher, p<0.05). At 
three months, even though the same general tendencies were observed, the differences were 
no longer significant.  
At nine days post-surgery, a decrease of the ipsilateral hind paw (left side) intensity, reflecting 
loss of weight support, was observed for all the conditions (Figure 6c). However, the left paw 
of the free GDNF-treated rats displayed a 3.6-fold higher intensity than the GDNF 
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microsphere-treated and the non-treated operated animals (p<0.05). Over time, a steady 
increase of the ipsilateral hind paw intensity for free GDNF-treated rats was recorded, 
whereas the same parameter was more than 3-fold lower for the GDNF microsphere-loaded 
hydrogel treated rats and non-treated operated animals (p<0.001).  
 
4 Discussion 
The expression levels of some growth factors, such as GDNF, are highly upregulated 
during the initial hours post-SCI and then quickly downregulated during the following days 
(Gerin et al., 2011). In this report, we incorporated GDNF, either free or encapsulated in 
microspheres, in an injectable alginate:fibrinogen hydrogel, and we evaluated the influence of 
GDNF-controlled delivery on hemisected spinal cord neurite outgrowth and functional 
recovery. 
GDNF controlled release was achieved both when the GDNF was incorporated free and 
when it was incorporated in microspheres in the hydrogel. As expected, faster release was 
observed when the free GDNF was incorporated into hydrogels as compared with the 
microspheres. The GDNF release kinetics and the burst release were much slower when the 
microspheres were incorporated into the alginate:fibrinogen hydrogel than when they were 
directly incubated in PBS (Garbayo et al., 2009). This difference can be explained by the 
hindered diffusion of GDNF across the PLGA-hydrogel boundary (Stanwick et al., 2012), by 
interactions between the alginate and GDNF, or by slower microsphere degradation. Most 
likely, a combination of these factors was involved. An assay performed on PC-12 cells 
demonstrated the preserved activity of released GDNF. Given that the GDNF incorporation in 
the alginate:fibrinogen hydrogel occurred during a very mild gelation process, the 
preservation of GDNF activity was expected. 
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When injected into a rat spinal cord hemisection model, the GDNF-loaded hydrogels 
elicited a different tissue response than observed for the non-treated operated animals. More 
homogenous and denser tissues were observed in the hemisections. The tendency to see 
differences in tissue organization at the lesion site in treated animals may be due to the 
hydrogel itself or could be simply a result of filling the initial tissue void (Cholas et al., 2012).  
Hemisections filled with free GDNF-loaded hydrogel displayed more neurofilament 
staining than GDNF microsphere-filled lesions or non-treated operated animals. 
Neurofilament staining decreased over time for the non-treated and free GDNF-treated rats 
but did not decrease for the GDNF microsphere-treated rats. GDNF is one of several potent 
neurotrophic factors that regulate many critical behaviors of neurons, including neurite 
branching and neuroprotection (Cholas et al., 2012) (des Rieux et al., unpublished data). The 
greater neurofilament staining observed at 6 weeks in the hydrogel-filled lesions of free 
GDNF-treated rats compared with the GDNF microsphere-treated animals might have been 
due to a rapid release of enough GDNF to stimulate neurite growth. GDNF mRNA expression 
is highly upregulated by 8 hours post-injury (a 6-fold increase compared with control) and is 
4-fold downregulated compared with the control from 12 hours to 12 weeks post-injury 
(Gerin et al., 2011). In addition, when exogenous GDNF is applied immediately or within 30 
minutes over the traumatized area, it significantly enhances cell viability and survival 
(Sharma, 2006). These results suggest that the injured spinal cord needs to be stimulated by 
an exogenous supply of GDNF to compensate for the loss of endogenous expression. 
Therefore, early GDNF delivery followed by a sustained release lasting up to 12 weeks or 
until behavioral changes are observed should promote cell survival (Hill et al., 2008). The 
GDNF fast release kinetics could explain why neurofilament staining observed 3 months post-
injury in the free GDNF treated rats was lower than at 6 weeks. However, neurofilament 
staining in the GDNF microsphere-treated rats did not diminish and was close to being 
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significantly higher than the staining in the controls (significant for α=0.1). This may be 
related to the low but sustained GDNF release from microsphere-loaded hydrogel 
(approximately 6 ng/day).  
Growing neurites were mainly observed at the lesion periphery and in the surrounding 
tissue but not directly within the lesion. The highest GAP43 immunoreactivity was observed 
for rats treated with GDNF microsphere-loaded hydrogels. Several studies have shown that 
GDNF administration following SCI significantly increases both the number of myelinated 
axons and the total number of regenerating axons (Iwase et al., 2005; Zhang et al., 2009). 
Another study reported an increased number of axons regrowing into Schwann cell grafts 
when GDNF treatment was provided and attributed this response either to a higher number of 
neurons that regrew their axons or to branching of existing axons (Zhang et al., 2009). The 
greater number of growing neurites detected in the periphery of the lesion in GDNF 
microsphere-treated rats in our study could be due to a prolonged action of GDNF over time, 
even after hydrogel degradation. Indeed, GDNF encapsulation in microspheres confers 
protection and sustained release of GDNF, whether microspheres are incorporated into a 
hydrogel or released in the surrounding tissues. As the hydrogel slowly degrades, the 
microspheres detach and migrate/diffuse through the tissue from their injection site and 
continue to deliver GDNF, whereas free GDNF is released and quickly degraded. Thus, we 
hypothesize that free GDNF is released within and close to the lesion site and has to act 
quickly to be efficient in the immediate vicinity and provide a local effect. However, GDNF 
microspheres should act for longer periods, increasing the GDNF half-life and stimulating 
neurite growth around the lesion by diffusion of GDNF into surrounding tissues. In addition, 
GDNF-treated spinal cords displayed apparently less GFAP staining and more endothelial and 
nerve fiber infiltration in the lesion site. Some level of organization was also visible, 
particularly in the spinal cords injected with GDNF microsphere-loaded hydrogels. Deng et 
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al. reported that GDNF treatment significantly reduced the production of GFAP and 
chondroitin sulfate proteoglycans (CSPGs) in both in vitro and in vivo models (Deng et al., 
2011). Regarding tissue organization, the hydrogel itself would most likely provide a 
mechanical support for axonal and blood vessel growth in addition to delivering growth 
factors. The main drawback of the hydrogel is the lack of directionality.  
The last part of our study was dedicated to the evaluation of the impact of GDNF 
delivery on functional recovery of treated animals. Free GDNF-loaded hydrogel-treated 
animals showed improved functional outcome after SCI compared to non-operated animals 
and even compared to GDNF microsphere-loaded hydrogels. Significant improvements were 
observed for paw angle of hind paws and left hind paws intensity parameters. These data 
suggest that an early sustained GDNF delivery from an alginate hydrogel, as obtained by 
treatment with free-GDNF hydrogels, is associated with better functional outcome than a 
slower GDNF release that is more sustained. As free-GDNF was also associated with the 
highest degree of neurofilament staining, functional outcomes in our investigation were better 
with early increases in neurofilament staining within the lesion site. Despite a higher degree 
of GAP43 staining and an increase of neurofilament staining over the course of three months, 
GDNF microsphere-treated rats did not show significant functional improvements. As such, it 
may be speculated that an improved functional outcome required early sustained GDNF 
delivery from an alginate hydrogel that may have induced an important degree of 
neurofilament survival or early growth in and around the lesion site. However, it would be 
over-simplistic to draw a direct line between neuroprotection and functional recovery, 
particularly as neurofilament immunoreactivity in the lesion site significantly decreased 3 
months post-surgery, whereas the Catwalk™ parameters were still significantly superior for 
the free GDNF treatment compared with the GDNF microspheres. In addition, the neurite 
growth that was observed within the lesions is encouraging but represents only the very first 
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step in the spinal cord healing process. Additional processes that limit spinal cord 
regeneration, and ultimately functional recovery, need to be addressed. These include the 
reestablishment of functional connections between the rostral and caudal sides of the lesion. 
Other parameters might also influence the functional outcome, such as neuropathic pain. 
Indeed, the intensity parameter of the Catwalk™ has previously been correlated with 
neuropathic pain behavior such as mechanical allodynia (Vrinten and Hamers, 2003). GDNF 
has potent analgesic effects (Boucher et al., 2000) and it might, therefore, be possible that 
early delivery of a high enough dose of GDNF would also reduce neuropathic pain in our 
investigation, thereby improving the rat walking pattern. The pain-reducing effect of GDNF 
has also been reported in an animal model of spinal cord injury. A mitigation of allodynia was 
noted when spinally injured mice received a transplant of GDNF producing-embryonic neural 
stem cell (NSC) as compared to NSC alone; this difference correlated with the level of 
CGRP/GAP43 immuno-reactivity and sprouting observed in the cervicothoracic dorsal horns 
(Macias et al., 2006). Both allodynia- and CGRP/GAP43-positive afferent sprouting were 
lower in the GDNF-transfected group compared with the NSC alone. Non-directed axonal 
sprouting might also cause (Berger et al., 2011). Kalous et al. provided evidence that the 
anatomical reorganization of sensory and nociceptive dorsal horn circuits rostral to an injury 
could factor in the development or maintenance of SCI pain (Kalous et al., 2009). The effect 
of GDNF on CGRP/GAP43 immunoreactivity might, thus, be both protective and analgesic 
on SCI-evoked neuropathic pain (Macias et al., 2006). 
 
5 Conclusion 
Our hypothesis was that GDNF-loaded injectable hydrogels would stimulate neurite growth 
and functional recovery after SCI. We demonstrated that local GDNF delivery from 
alginate:fibrinogen hydrogel gelifying in situ significantly increased the ingrowth of neurites 
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in and around the site of spinal cord hemisection. Free GDNF delivery elicited more 
neurofilament staining at the lesion, whereas GDNF microspheres induced more neurite 
growth around the lesion. The animals treated with free GDNF-loaded hydrogel experienced 
superior functional recovery compared with the animals treated with GDNF microsphere-
loaded hydrogels and non-treated animals. We hypothesize that these results could be linked 
to different GDNF release profiles that influence GDNF actions on damaged spinal cord.  
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